drugset / Trial / NCT06613750

Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity

NCT06613750 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets versus metformin in treatment-naïve patients with type 2 diabetes mellitus (T2DM) and glucotoxicity. The trial assesses glycemic control, patient compliance, and adverse events over a 12-week period using a randomized controlled design to determine the non-inferiority of the combined treatment.

Timeline

Start
2024-06-01
Primary completion
2024-06-30
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gliclazide Small molecule 30 mg —
Subject Gliclazide Small molecule 120 mg —
Comparator Metformin Small molecule 500 mg —
Comparator Metformin Small molecule 2000 mg —
Subject Sitagliptin Small molecule 100 mg —